ArticleFrontiers in immunology2022

A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.

Xukai Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.